Emerald Health rises after receiving cannabis license

Shares of Emerald Health Therapeutics (Emerald Health Therapeutics Stock Quote, Chart, News: TSXV:EMH) are up today after the company announced its wholly owned subsidiary, Emerald Health Botanicals, had received a supplemental license from Health Canada authorizing it to produce cannabis oils and capsules. The company also received approval for two additional production rooms, something management says will “significantly” increase its growing capacity.

“We are excited by what the supplemental licence means to patients who would like to access their medicine in a variety of forms. We are uniquely positioned to provide medical cannabis to patients in oils and capsules, that can be properly dosed and assessed through clinical studies, given our teams extensive experience in drug development,” said Dr. chairman Avtar Dhillon. “We are committed to providing a consistent, quality product and have acquired the equipment to begin production of cannabis oils immediately.”

On April 1st of last year, new rules were introduced that changed the Canadian government’s approach to marijuana and laid the groundwork for what many think is the inevitable legalization of the substance. In the meantime, a half-step was taken. Under the Marijuana for Medical Purposes Regulations (MMPR), Health Canada no longer supplies marijuana to those with a proven medical need but instead has tasked licensed commercial producers (LPs) to do so.

In June, in a 7-0 ruling, the Supreme Court acquitted Owen Smith of trafficking charges. Smith, the head baker for Victoria-based Cannabis Buyers Club of Canada, was arrested when police found items such as dried marijuana and cannabis cookies on site. Subsequently, Health Canada has now licensed some LPs to produce and sell cannabis oil, fresh marijuana buds and leaves and dried marijuana. The agency has created a new category on its website: “Licensed Producers of fresh marijuana and cannabis oil”.

At press time, shares of Emerald Health were up 11.1% to $0.40.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: emh
Staff

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago